Qureight's fibrosis imaging biomarker selected by Contineum Therapeutics as a secondary endpoint in Phase 2 PROPEL-IPF clinical trial
Qureight, an end-to-end imaging company providing enterprise-grade imaging and precision endpoints for clinical trials for lung and heart disease, and Contineum Therapeutics, Inc. (Contineum), a clinical-stage biopharmaceutical company pioneering differentiated small molecule therapies for inflammatory and fibrotic diseases with significant unmet need, today announced that Qureight's Fibr8™…
Read original article on The Medical News →Related news
-
Childhood cancer cells shape-shift to spread without genetic mutations
United Kingdom
-
AI assesses what really matters to people in health care—well-being
United Kingdom
-
Early trial results suggest potential new treatment for stiff person syndrome
United Kingdom
-
US youths see nearly 4,000 food marketing messages on digital media each year
United Kingdom
-
A brief history of the food pyramid – and its many false starts
Australia
-
Fish Stocks Thrive Thanks to This Pink Seaweed and Locals Who Protected It
United Kingdom
-
It takes a neighborhood to keep kids active
United Kingdom
-
Two-year study will examine how gender-affirming hormone therapy affects energy use and blood vessel function
United Kingdom